Azamian Bobak R. — SEC insider filings
SEC reporting owner CIK 1827672. 66 insider filings on record with FilingPulse; latest filed 2026-11-17.
Transaction summary — filings shown
Covers the 50 most recent of 66 filings on record, filed 2022-11-14 to 2026-11-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 63 legs across 43 filings — 469,686 shares, $14,399,578 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 23.
- Largest priced transaction: sale of 99,726 shares @ $20.04 ($1,998,509) in Tarsus Pharmaceuticals, Inc., filed 2023-07-21.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | President/CEO and Board Chair, Director | 50 | — | 63 legs · 469,686 sh · $14,399,578 | 23 |
Insider filings — Azamian Bobak R.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 10,000 @ $80.31 | EDGAR |
| 2026-09-09 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 7,100 @ $90.27 · Sale (S): 2,900 @ $91.27 | EDGAR |
| 2026-09-03 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 10,000 @ $80.06 | EDGAR |
| 2026-06-22 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 4,582 @ $61.24 · Sale (S): 5,418 @ $61.81 | EDGAR |
| 2026-03-19 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 10,972 @ $69.42 · Sale (S): 11,667 @ $68.71 · Sale (S): 11,964 @ $67 | EDGAR |
| 2026-03-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 66,274 · Option exercise (M): 11,300 (derivative) @ $0 · Option exercise (M): 16,975 (derivative) @ $0 · Option exercise (M): 23,121 (derivative) @ $0 · Option exercise (M): 14,878 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 96,723 (derivative) @ $0 · Grant/award (A): 60,776 (derivative) @ $0 | EDGAR |
| 2025-12-30 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 5,443 @ $82.41 · Sale (S): 557 @ $83.54 | EDGAR |
| 2025-12-08 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Gift (G): 51,885 @ $0 | EDGAR |
| 2025-09-26 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 6,000 @ $55.37 | EDGAR |
| 2025-08-13 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 6,000 @ $50 | EDGAR |
| 2025-03-26 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 6,000 @ $50 | EDGAR |
| 2025-03-20 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 7,131 @ $46.29 · Sale (S): 8,551 @ $47.40 · Sale (S): 8,534 @ $50.11 | EDGAR |
| 2025-03-18 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 51,395 · Option exercise (M): 11,299 (derivative) @ $0 · Option exercise (M): 16,975 (derivative) @ $0 · Option exercise (M): 23,121 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 90,736 (derivative) @ $0 · Grant/award (A): 59,512 (derivative) @ $0 | EDGAR |
| 2024-03-19 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 28,274 · Sale (S): 10,415 @ $30.60 · Option exercise (M): 11,299 (derivative) @ $0 · Option exercise (M): 16,975 (derivative) @ $0 | EDGAR |
| 2024-03-11 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 136,947 (derivative) @ $0 · Grant/award (A): 92,485 (derivative) @ $0 | EDGAR |
| 2023-12-29 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 8,000 @ $20.22 | EDGAR |
| 2023-12-22 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 9,443 @ $19.96 · Sale (S): 30,557 @ $20.36 | EDGAR |
| 2023-11-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 2,896 @ $18.01 · Sale (S): 4,904 @ $18.54 · Sale (S): 200 @ $19.28 | EDGAR |
| 2023-10-20 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 8,000 @ $13.24 | EDGAR |
| 2023-09-22 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 8,000 @ $17.21 | EDGAR |
| 2023-08-25 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 8,000 @ $17.23 | EDGAR |
| 2023-07-21 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 4,174 @ $19.28 · Sale (S): 99,726 @ $20.04 | EDGAR |
| 2023-07-14 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 9,000 @ $17.35 | EDGAR |
| 2023-06-23 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 8,000 @ $18.63 | EDGAR |
| 2023-06-16 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 9,000 @ $18.58 | EDGAR |
| 2023-06-12 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 3,100 @ $20.01 | EDGAR |
| 2023-05-19 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 8,000 @ $15.90 | EDGAR |
| 2023-05-12 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 9,000 @ $16.80 | EDGAR |
| 2023-05-02 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 4,278 @ $15.13 · Sale (S): 5,841 @ $15.10 | EDGAR |
| 2023-04-25 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 2,311 @ $15.03 | EDGAR |
| 2023-04-21 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 8,000 @ $13.60 | EDGAR |
| 2023-03-23 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 679 @ $12.89 · Sale (S): 709 @ $12.64 · Sale (S): 737 @ $12.15 | EDGAR |
| 2023-03-21 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 795 @ $13.28 · Sale (S): 741 @ $12.61 | EDGAR |
| 2023-03-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 8,000 @ $13.79 · Option exercise (M): 11,299 · Sale (S): 791 @ $13.43 · Option exercise (M): 11,299 (derivative) @ $0 | EDGAR |
| 2023-03-10 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 100,242 (derivative) @ $0 · Grant/award (A): 67,900 (derivative) @ $0 | EDGAR |
| 2023-03-10 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 4,853 @ $15.02 · Sale (S): 717 @ $15.01 | EDGAR |
| 2023-02-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 8,000 @ $15.28 | EDGAR |
| 2023-02-10 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 9,000 @ $15.14 | EDGAR |
| 2023-01-25 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 4,856 @ $15.45 | EDGAR |
| 2023-01-24 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 411 @ $15 | EDGAR |
| 2023-01-20 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 8,000 @ $14.56 · Sale (S): 240 @ $15 | EDGAR |
| 2023-01-13 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 3,904 @ $15.11 | EDGAR |
| 2023-01-11 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 729 @ $15.15 · Sale (S): 905 @ $15.17 | EDGAR |
| 2022-12-22 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 8,000 @ $14.57 | EDGAR |
| 2022-12-20 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 535 @ $15.01 | EDGAR |
| 2022-12-16 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 6,420 @ $15.08 | EDGAR |
| 2022-11-18 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 7,255 @ $16.81 · Sale (S): 745 @ $17.31 | EDGAR |
| 2022-11-14 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Sale (S): 9,000 @ $17.87 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1827672 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs